"Skip to content\nHome\nProducts\nClinical\nNews\nInvestors\nAbout Us\nContact Us\nINVEST NOW\nNEWS\nCEO Andrew Simpson Discusses HeartSciences’ AI-ECG Solutions \nApril 14, 2025\n\nHeartSciences’ CEO Andrew Simpson discusses heart disease and our AI-ECG solutions using both MyoVista hardware and MyoVista Insights cloud-based solutions\n\nSee the video: https://youtu.be/OrR2RtK3qvA\n\nMillions of ECGs are performed every week, however, for decades these tests have largely remained unchanged. Conventional ECGs are easy and quick to perform, but unfortunately do not detect most heart disease conditions.\n\nArtificial Intelligence-Enhanced Electrocardiography (AI-ECG) is set to transform cardiovascular medicine. AI-ECG allows previously unseen disease to be identified and radically expands the clinical usefulness of an ECG.\n\nContacts\nMEDIA RELATIONS\n\nGene Gephart\nDirector of Marketing\n+1-682-244-2578 (US)\n\ngene.gephart@heartsciences.com\nINVESTOR CONTACT\n\nMark Komonoski – Partner\nIntegrous Communications\nDirect: 877-255-8483\n\ninvestorrelations@heartsciences.com\nwww.integcom.us\n